Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(562 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(245 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(52 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Mostrar 6 subcategorías más
Se han encontrado 2242 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
VEGFR-2-IN-56
VEGFR-2-IN-56 (compound 12e) exhibits the strongest inhibition activity against VEGFR-2, with an IC50 value of 45.9 nM.Forma y color:Odour SolidPetosemtamab (FUT8-KO)
Petosemtamab (FUT8-KO) is a variant of Petosemtamab with the fucosyltransferase 8 gene (FUT8) knocked out. Petosemtamab is a monoclonal antibody (mAb) targeting EGFR (with a Kd of 0.22 nM) and LGR5 (with a Kd of 0.86 nM). This antibody disrupts EGFR signaling and causes receptor degradation in LGR5+ cancer cells. It is applicable in research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).Forma y color:Odour LiquidNRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Fórmula:C43H51N11O6Forma y color:SolidPeso molecular:817.94MS9449
CAS:MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Fórmula:C60H76ClFN10O8SPureza:98%Forma y color:SolidPeso molecular:1151.82Tephrosin
CAS:Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.Fórmula:C23H22O7Pureza:98%Forma y color:SolidPeso molecular:410.42Simotinib hydrochloride
CAS:Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.Fórmula:C25H27Cl2FN4O4Forma y color:SolidPeso molecular:537.41ARRY-380 (analog )
CAS:ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.Fórmula:C29H27N7O4SPureza:99.82%Forma y color:SolidPeso molecular:569.63Ref: TM-T2518
1mg34,00€2mg47,00€5mg71,00€10mg104,00€25mg170,00€50mg253,00€100mgA consultar1mL*10mM (DMSO)92,00€DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Forma y color:LiquidSecretin, canine
CAS:Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.Fórmula:C131H222N44O41Pureza:98%Forma y color:SolidPeso molecular:3069.43EGFR/VEGFR2-IN-1
EGFR/VEGFR2-IN-1 (Compound 10e) serves as an inhibitor for VEGFR-2 and EGFR, with respective IC50 values of 0.26 and 0.14 μM. It inhibits microtubule protein polymerization with an IC50 of 40.9 μM and induces cell apoptosis (Apoptosis). EGFR/VEGFR2-IN-1 is applicable in research related to anti-leukemia and anti-lymphoma treatments.Forma y color:Odour SolidQL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Fórmula:C25H20ClN5O2Pureza:99.25%Forma y color:SoildPeso molecular:457.91TL13-112
CAS:TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).Fórmula:C49H60ClN9O10SPureza:98%Forma y color:SolidPeso molecular:1002.57FAK-IN-14
CAS:FAK-IN-14 is a FAK inhibitor that induces apoptosis and cell cycle arrest. FAK-IN-14 has a more significant inhibitory effect on FAK, FGFR1 and Pyk2.Fórmula:C21H24BrN7OSPureza:99.7%Forma y color:SoildPeso molecular:502.43BPC 157 (X acetate)
CAS:Body Protection Compound 157 (BPC 157) is a pentadecapeptide derived from BPC, identified in gastric juice, exhibiting diverse biological activities. At 2 µg/ml, BPC 157 enhances primary rat tendon fibroblast cell migration and F-actin formation. Furthermore, doses of 0.01 and 10 µg/kg, intraperitoneally (i.p.), mitigate paw swelling, bone erosion, and mononuclear cell infiltration in the joints of rats with rheumatoid arthritis induced by complete Freund's adjuvant (CFA). It also diminishes gastric ulcer size in rats caused by indomethacin, aspirin, or diclofenac at these doses. Additionally, BPC 157 reduces catalepsy duration and tremor severity in a mouse model of Parkinson's disease triggered by MPTP.Fórmula:C62H98N16O22XC2H4O2Forma y color:SolidPeso molecular:1419.54JBJ-09-063 TFA
JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.Fórmula:C33H30F4N4O5SForma y color:SolidPeso molecular:670.67EGFR T790M/L858R-IN-2
EGFRT790M/L858R-IN-2: selective inhibitor, IC50: 3.5 nM (mutant), 1290 nM (WT); reduces p-EGFR/AKT/ERK1/2, triggers apoptosis, G1 arrest, anti-cancer.Fórmula:C28H28FN7OForma y color:SolidPeso molecular:497.57HER2-IN-13
CAS:HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with anFórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Fórmula:C50H48N12O4Pureza:98%Forma y color:SolidPeso molecular:880.99Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Fórmula:C8H6BrN3SPureza:99.94%Forma y color:SolidPeso molecular:256.12SJF 1521
CAS:SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.Fórmula:C57H61ClFN7O9SPureza:99.20%Forma y color:SolidPeso molecular:1074.65Bevasiranib
CAS:Bevasiranib is a siRNA targeting VEGF production, key in choroidal neo-vascularization and wet AMD.Forma y color:SolidVEGFR-2-IN-55
VEGFR-2-IN-55 (Compound 30) is an effective VEGFR-2 kinase inhibitor with an IC50 of 1.24 nM and exhibits anti-tumor activity.Forma y color:Odour SolidTYVPANASL TFA
TYVPANASL TFA, a nine-amino-acid MHC I-binding CD8 T-cell epitope derived from HER2/neu, is utilized in the formulation of J-LEAPS vaccines [1].Forma y color:Odour SolidVEGFR-2/c-Met-IN-1
VEGFR-2/c-Met-IN-1 is a dual inhibitor targeting VEGFR-2 and c-Met with respective IC50 values of 138 nM and 74 nM, demonstrating antitumor activity [1].Pureza:98%Forma y color:Odour SolidAdenosine receptor modulator 1
Adenosine receptor modulator 1 acts as an inducer of collagen VII (C7). It enhances the expression of COL7A1 mRNA in donor-derived keratinocytes and, in synergy with Gentamicin, increases the overall levels of C7.Fórmula:C25H28N6O3Forma y color:SolidPeso molecular:460.53PROTAC FLT-3 degrader 3
PROTACFLT-3degrader 3 (compound 35) is a PROTAC degrader of FLT. It exhibits antiproliferative activity, with an IC50 value of 7.55 nM in MV4-11 cells.Fórmula:C48H44Cl2N10O6Peso molecular:926.28223VEGFR-2-IN-32
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2, exhibiting an inhibitory concentration (IC 50) of 8.93 nM, and demonstrates cytotoxic activity towards PC-3Fórmula:C15H12N4OPureza:98%Forma y color:SolidPeso molecular:264.28EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Fórmula:C49H53ClFN5O5Forma y color:SolidPeso molecular:846.43N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide
CAS:Phosphopeptide; binds to the src SH2 domain.Fórmula:C26H42N3O9PPureza:98%Forma y color:SolidPeso molecular:571.61BTK inhibitor 17
CAS:BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.Fórmula:C25H24N6O3Pureza:99.57% - 99.88%Forma y color:SolidPeso molecular:456.5Ref: TM-T9706
1mg89,00€5mg166,00€10mg250,00€25mg403,00€50mg532,00€100mg745,00€200mg982,00€1mL*10mM (DMSO)166,00€Anticancer agent 133
Compound Rh2 (Anticancer agent 133) is a cytotoxic and antimetastatic agent that induces cell cycle arrest, apoptosis, and autophagy.Fórmula:C24H19Cl3N5ORhPureza:98%Forma y color:SolidPeso molecular:602.71PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.
Fórmula:C43H43N9O4Forma y color:SolidPeso molecular:749.86Emodic acid
CAS:Emodic acid is a useful organic compound for research related to life sciences. The catalog number is T124807 and the CAS number is 478-45-5.Fórmula:C15H8O7Forma y color:SolidPeso molecular:300.222Os30
Os30 is a potent fourth-generation EGFR inhibitor, specifically targeting the EGFRC797S-TK mutation with IC50 values of 18 nM for EGFRDel19/T790M/C797S TK and
Pureza:98%Forma y color:Odour SolidPROTAC TYK2 degradation agent1
CAS:PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.Fórmula:C55H69N13O7SPureza:98%Forma y color:SolidPeso molecular:1056.28Arginyl-Glutamine
CAS:Arginyl-Glutamine (Arg-Gln) is a dipeptide nutritional supplement that protects neonatal mice from hyperoxia-induced lung injury, lowering VEGF levels.Fórmula:C11H22N6O4Pureza:95.2%Forma y color:SolidPeso molecular:302.33Caffeic acid-pYEEIE
CAS:Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).
Fórmula:C39H50N5O19PPureza:98%Forma y color:SolidPeso molecular:923.82LAE-102
LAE-102 is a monoclonal antibody that acts as an antagonist of activin receptor II-A (ACTRIIA/ACVR2). It shows potential for research in the fields of endocrine and metabolic disorders, oncology, and respiratory diseases.Forma y color:Odour LiquidMulti-kinase-IN-4
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.Fórmula:C21H20ClFN2OSPureza:98%Forma y color:SolidPeso molecular:402.91VEGFR-2-IN-36
VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstratedFórmula:C24H23N7O5Pureza:98%Forma y color:SolidPeso molecular:489.48FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.
Forma y color:Odour SolidSNIPER(ABL)-047
SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,Fórmula:C67H82F3N11O9SPureza:98%Forma y color:SolidPeso molecular:1274.5DSPE-PEG2000-A7R
DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Forma y color:Odour SolidCNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Fórmula:C48H68N10O9SPureza:98%Forma y color:SolidPeso molecular:961.18JAK-IN-15
CAS:JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).Fórmula:C22H23FN4O3SForma y color:SolidPeso molecular:442.51JAK 3 inhibitor IV
CAS:JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found toFórmula:C16H19NOPureza:98%Forma y color:SolidPeso molecular:241.33VEGFR2/HDAC1-IN-1
VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.Pureza:98%Forma y color:Odour SolidSJ10542
CAS:SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.Fórmula:C41H46N12O5SForma y color:SolidPeso molecular:818.95BCR-ABL-IN-3
CAS:BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.Fórmula:C20H17ClF2N4O3SForma y color:SolidPeso molecular:466.89SC209
CAS:SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.Fórmula:C27H44N4O4Forma y color:SolidPeso molecular:488.66Abicipar pegol
CAS:Abicipar pegol is an anti-VEGF DARPin for ocular diseases, reducing retinal thickness and leakage.Forma y color:LiquidSJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Fórmula:C41H45ClN8O7Pureza:98%Forma y color:SolidPeso molecular:797.3FLT3-IN-20
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.Fórmula:C28H33N7O2SForma y color:SolidPeso molecular:531.67SPP-037
SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.Fórmula:C36H50ClN3O9SForma y color:SolidPeso molecular:735.29563SOS1/EGFR-IN-2
SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.Fórmula:C25H29F3N4O3Forma y color:SolidPeso molecular:490.52PF15
CAS:PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Fórmula:C44H49N13O6Pureza:98%Forma y color:SolidPeso molecular:855.94VSLRGDTRG acetate
VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.Forma y color:Odour SolidEGFR-IN-140
EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.Fórmula:C27H37FN8O2Forma y color:SolidPeso molecular:524.633DSPE-PEG5000-GE11
DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.Forma y color:Odour SolidALK/ROS1-IN-5
ALK/ROS1-IN-5 (compound X4) is a selective inhibitor of ALK and ROS1 kinases, with IC50 values of 0.512 μM for ALK and 0.766 μM for ROS1. It inhibits H2228 cells with an IC50 of 0.034 μM and induces apoptosis in cancer cells in a dose-dependent manner. Additionally, ALK/ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells.
Fórmula:C32H28F2N4O3Forma y color:SolidPeso molecular:554.586MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.Fórmula:C52H72N12O11Pureza:97.70%Forma y color:SolidPeso molecular:1041.2Pulocimab
CAS:Pulocimab, an anti-VEGFR2 monoclonal antibody (mAb), is utilized in cancer research [1].Forma y color:LiquidSNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFórmula:C60H77ClN12O9SPureza:98%Forma y color:SolidPeso molecular:1177.85HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Fórmula:C60H69N17O11SForma y color:SolidPeso molecular:1236.36SNIPER(ABL)-044
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving aFórmula:C51H64F3N9O8SPureza:98%Forma y color:SolidPeso molecular:1020.17AZ12672857
CAS:AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.
Fórmula:C26H30N8O2Pureza:98.99%Forma y color:SolidPeso molecular:486.57AS2553627
CAS:AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.Fórmula:C18H19N5OForma y color:SolidPeso molecular:321.38DSPE-PEG3400-A7R
DSPE-PEG3400-A7R is a PEG compound comprising DSPE and the tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Forma y color:Odour SolidEGFR-IN-102
CAS:EGFR-IN-102 (compound 6), an orally active EGFR inhibitor, demonstrates an IC 50 of 2 nM and is utilized for research in non-small-cell lung cancer [1].Fórmula:C37H37F2N7O2SPeso molecular:681.80VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Fórmula:C29H27N9OPureza:98%Forma y color:SolidPeso molecular:517.58RR-src
CAS:Tyrosine kinase substrate peptideFórmula:C64H106N22O21Pureza:98%Forma y color:Lyophilized PowderPeso molecular:1519.66PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Fórmula:C39H45ClN7O5PForma y color:SolidPeso molecular:758.245LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Fórmula:C29H31F3N6O2SForma y color:SolidPeso molecular:584.66FAK PROTAC B5
CAS:FAK PROTAC B5: a degrader with 14.9 nM IC50, strong degradation, anti-growth, good plasma stability, and fair permeability.Fórmula:C41H43ClN10O7Forma y color:SolidPeso molecular:823.3HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Fórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96FAK-IN-24
CAS:FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.Fórmula:C39H45Cl2F3N8O3Forma y color:SolidPeso molecular:801.728AG-825
CAS:AG-825（Tyrphostin C15） is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (TyrphostinFórmula:C19H15N3O3S2Pureza:99.52%Forma y color:Yellow SolidPeso molecular:397.47Ref: TM-T14138
1mg34,00€5mg66,00€10mg105,00€25mg222,00€50mg371,00€100mg597,00€500mg1.234,00€1mL*10mM (DMSO)73,00€SNIPER(ABL)-039
CAS:SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 ofFórmula:C54H68ClN11O9S2Pureza:98%Forma y color:SolidPeso molecular:1114.77FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Fórmula:C29H35N7O5Forma y color:SolidPeso molecular:561.63AXL/Angiokinase-IN-1
AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.Fórmula:C31H34ClN5O2Forma y color:SolidPeso molecular:544.09Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
CAS:Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK.Fórmula:C32H46N5O17PPureza:98%Forma y color:SolidPeso molecular:803.71LC-SF-14
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.Fórmula:C44H50Cl3N13O5SForma y color:SolidPeso molecular:977.28442HDS 029
CAS:HDS 029 has a wide range of applications in life science related research.Fórmula:C17H11ClFN5OForma y color:SolidPeso molecular:355.76PKM2/PDK1-IN-1
PKM2/PDK1-IN-1, a shikonin derivative, dual inhibitor of PKM2/PDK1, halts NSCLC growth, triggers apoptosis, and boosts ROS affecting cell death pathways.Fórmula:C36H43NO7S3Forma y color:SolidPeso molecular:697.92PROTAC BTK Degrader-13
PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]Fórmula:C33H30N6O7Forma y color:SolidPeso molecular:622.63Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPureza:98%Forma y color:SolidEGFR-IN-153
EGFR-IN-153 (Compound 5l) is an EGFR inhibitor that suppresses the proliferation of MDA-MB-231 cells with an IC50 of 0.73 μM and induces apoptosis. It is applicable for research in breast cancer.Forma y color:Odour SolidWZH-17-002
WZH-17-002 is an ALKPROTAC degrader based on WZH-15-125, with a DC50 of 25 nM. This compound enhances the efficacy against ALK mutations that confer resistance to Lorlatinib. Moreover, WZH-17-002 significantly reduces resistance in ALK fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196M xenograft mouse models.Forma y color:Odour SolidEGFR-IN-84
EGFR-IN-84 (Compound 6g), an EGFR inhibitor with an IC50 of 24 nM, impedes the growth of A549 cells with an IC50 value of 1.537 μM and is utilized for lungFórmula:C25H20N6O3S2Pureza:98%Forma y color:SolidPeso molecular:516.59EGFR-IN-131
EGFR-IN-131 (compound 3a) is an efficacious EGFR inhibitor capable of crossing the blood-brain barrier, with an IC50 value of 272.9 nM. This compound exhibits anti-proliferative activity, induces cellular apoptosis (apoptosis), and causes cell cycle arrest in the G0/G1 phase. Additionally, EGFR-IN-131 reduces the protein expression of p-EGFR.Fórmula:C26H23FN4O2SForma y color:SolidPeso molecular:474.55Zeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Fórmula:C56H56F6N8O12Forma y color:SolidPeso molecular:1147.098AKN-028
CAS:AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
Fórmula:C17H14N6Pureza:99.88%Forma y color:SolidPeso molecular:302.33BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Fórmula:C58H65F2N11O8Forma y color:SolidPeso molecular:1082.224Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39BIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Fórmula:C28H34N10O2Forma y color:SolidPeso molecular:542.648EGFR-IN-76
CAS:EGFR-IN-76 is a potent EGFR inhibitor.Fórmula:C30H30ClFN6O2Pureza:97.02% - 97.72%Forma y color:SolidPeso molecular:561.05SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Fórmula:C44H59ClN10O8SPureza:98%Forma y color:SolidPeso molecular:923.52EGFR-IN-86
EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cellFórmula:C20H21N7O2SPureza:98%Forma y color:SolidPeso molecular:423.49GSK143
CAS:GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.Fórmula:C17H22N6O2Forma y color:SolidPeso molecular:342.403
